lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
If this occurs and the user takes a dose comparable to their previous use, the user may experience drug effects that are much greater than expected, potentially resulting in an overdose. It has been speculated that an unknown portion of heroin-related deaths are the result of an overdose or allergic reaction to quinine, which may sometimes be used as a cutting agent.
=== Controversies === In 2018 UA received funding from the Pioneer Fund, a non-profit institute which promotes scientific racism and eugenics. The funds were applied for by Aurelio Jose Figueredo, who directs the graduate program on human behavior and evolutionary psychology. Funds from the grant were used by Figueredo to attend the 2016 London Conference on Intelligence, where presentations on eugenics are given. Figueredo has also reviewed papers for Mankind Quarterly, a journal which has advocated for racial hierarchy. Figueredo has disavowed eugenics and racial inferiority.
RGFP966, or RGFP-966, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a highly selective HDAC3 inhibitor. The drug is the most commonly used selective HDAC3 inhibitor in research.
Sources: en.wikipedia.org
By the early 2000s most lichen phylogenies analysed 3–5 genes (a few thousand base pairs in total). Frequently used loci were nuLSU rDNA, ITS (the standard barcode), and protein-coding fragments such as RPB1/2 or β-tubulin. Multilocus trees clarified family- and order-level relationships. They confirmed that almost all lichen-forming ascomycetes fall into three classes: Lecanoromycetes (the largest, e.g., Parmeliaceae, Lecanoraceae, Physciaceae), Eurotiomycetes (e.g., some Verrucaria), and Sordariomycetes (e.g., Graphidaceae). A small minority occur in the Basidiomycota (several agaric and clavarioid orders) or in smaller ascomycete classes. Thus molecular work placed lichens securely within the fungal tree, as Santesson had anticipated. The results prompted extensive revision; orders and families were reorganized to remove polyphyletic groups. For example, the pre-molecular 'Lecanorales' was divided into several orders (Lecanorales, Peltigerales, Teloschistales, etc.) after DNA data showed that superficially similar fruiting bodies did not imply close relationship. By the late 2000s a molecular phylogeny was routine in new taxonomic studies. Traditional methods remained important alongside molecular approaches. Morphology and chemistry remained essential: they guided sampling, framed hypotheses, and provided the diagnostic traits needed to circumscribe taxa. Many new species—particularly from biodiversity-rich regions—were still described from morphology alone or with a single DNA barcode.
The LCPO method uses a linear approximation of the two-body problem for a quicker analytical calculation of ASA. The approximations used in LCPO result in an error in the range of 1-3 Ų. In 2011, a method was presented that calculates ASA fast and analytically using a power diagram. Accessible surface area is often used when calculating the transfer free energy required to move a biomolecule from an aqueous solvent to a non-polar solvent, such as a lipid environment. The LCPO method is also used when calculating implicit solvent effects in the molecular dynamics software package AMBER. It is recently suggested that (predicted) accessible surface area can be used to improve prediction of protein secondary structure.
Without this reactivity reserve, a reactor shutdown would preclude its restart for several tens of hours until 135I/135Xe sufficiently decays, especially shortly before replacement of spent fuel (with high burnup and accumulated nuclear poisons) with fresh fuel. Fluid fuel reactors cannot develop xenon inhomogeneity because the fuel is free to mix. Also, the Molten Salt Reactor Experiment demonstrated that spraying the liquid fuel as droplets through a gas space during recirculation can allow xenon and krypton to leave the fuel salts.
Sources: en.wikipedia.org
The main use of calcium sulfate is to produce plaster of Paris and stucco. These applications exploit the fact that calcium sulfate which has been powdered and calcined forms a moldable paste upon hydration and hardens as crystalline calcium sulfate dihydrate. It is also convenient that calcium sulfate is poorly soluble in water and does not readily dissolve in contact with water after its solidification.
=== Bellido cabinet === The Bellido Cabinet, made by Castillo, was widely criticized in the media and from various political opponents of the new government. Some journalists, like Fernando Vivas from El Comercio, called it the "shock cabinet," due to the belief that it was meant to bait Congress into denying confidence twice so that Congress could be shut down, as it was during the 2019–2020 Peruvian constitutional crisis. A congressman from Free Peru claimed that Congress was attempting to impeach Castillo, and warned that if trust is denied twice then Congress will be dissolved. Vice President Dina Boluarte said that Congress would not be dissolved. The cabinet led to the Purple Party and We Are Peru leaving the government coalition, and sparked backlash from Congress and sectors of the public. President Pedro Castillo appointed the new head of the Joint Command of the Armed Forces (CC. FF. AA.); on 3 August, Manuel Gómez de la Torre replaced General César Astudillo as General Commander. Changes were also made for the general commanders of the Army, Navy, and Air Force. On 6 October 2021, President Castillo announced the resignation of the Guido Bellido cabinet, citing instability in the country. Under Peruvian law, the resignation of the Prime Minister dissolves the cabinet. A new cabinet was formed, led by Mirtha Vásquez.
== Chemical properties == At physiological pH, the ε-amino group (–NH2) of the lysine residue exists almost entirely in its protonated form (–NH3+), whereas the carboxyl group (–COOH) of the malonyl group exists almost entirely in its deprotonated form (–COO-). Through the covalent attachment of a malonyl group to the ε-amino group, the lysine residue loses its positive charge and assumes the negative charge of the malonyl group, resulting in a charge shift from +1 to −1. This complete reversal of charge is thought to disrupt ionic interactions both within the protein itself and with negatively charged components of nucleotides, proteins and small molecules. Such alterations can occur at multiple lysine residues within a single protein, although their overall frequency varies considerably across the proteome. In mouse liver, for example, about half of all malonylated proteins contain a single site, while the frequency decreases sharply beyond four sites and only a few are extensively modified, the most heavily modified enzyme being carbamoyl‑phosphate synthetase 1 (CPS1) of the urea cycle with 31 sites. In the context of other lysine acylations, malonylation can be positioned as follows: While acetylation neutralizes lysine's positive charge, malonylation introduces a negative one, placing it among the acidic acylations alongside methylmalonylation, succinylation, glutarylation, 3‑hydroxy‑3‑methylglutarylation, 3‑methylglutaconylation, and 3‑methylglutarylation.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.